Patents Examined by D Margaret M Seaman
  • Patent number: 10202339
    Abstract: Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: February 12, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • Patent number: 10202347
    Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: February 12, 2019
    Assignee: MICROBIAL CHEMISTRY RESEARCH FOUNDATION
    Inventors: Manabu Kawada, Hikaru Abe, Takumi Watanabe, Hiroyuki Inoue, Shun-ichi Ohba, Chigusa Hayashi, Masayuki Igarashi
  • Patent number: 10195186
    Abstract: The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motoneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as Alzheimer's disease and Parkinson's disease.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 5, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Philip James Maltas, Stephen Watson, Morten Langgård, Laurent David
  • Patent number: 10196386
    Abstract: Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 5, 2019
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio Rancati, Andrea Rizzi, Laura Carzaniga, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Patent number: 10196361
    Abstract: Provided are a sodium salt of a uric acid transporter inhibitor and a crystalline form thereof, In particular, provided are a uric acid transporter (URAT1) inhibitor 1-((6-bromo-quinoline-4-yl)thio)cyclobutyl sodium formate (the compound of formula (I)), a crystal form I, and preparation method thereof. The obtained crystal form I of the compound of formula (I) has a good crystal form stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, and can be better used in clinical treatment.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: February 5, 2019
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Guaili Wu, Zhenjun Qiu, Yunpeng Su, Xi Lu
  • Patent number: 10196377
    Abstract: A compound having the following formula: or a pharmaceutically acceptable salt thereof. A medicament or pharmaceutical composition contains the compound. A method of treating a respiratory tract disease includes administering to a patient an effective amount of a compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 5, 2019
    Assignee: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
    Inventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova
  • Patent number: 10189788
    Abstract: The present application relates to novel substituted N,2-diarylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and/or inflammatory disorders.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: January 29, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Beck, Tobias Thaler, Raimund Kast, Daniel Meibom, Mark Meininghaus, Carsten Terjung, Martina Delbeck, Klemens Lustig, Uwe Muenster, Britta Olenik
  • Patent number: 10183997
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: January 22, 2019
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yun Hee Park, Jeong Hee Ryu, Ho Young Song, Jeiwook Chae, Chul-Woong Chung, Ji Eun Jung, Hyo Jung Choi
  • Patent number: 10174017
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: January 8, 2019
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill M. Sturdivant, Susan M. Royalty
  • Patent number: 10166214
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: January 1, 2019
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Patent number: 10159731
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: December 25, 2018
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • Patent number: 10160726
    Abstract: This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: December 25, 2018
    Assignee: Novartis AG
    Inventors: Javier de Vicente Fidalgo, Haiying He, Cheng Hu, Zhigan Jiang, Xiaolin Li, Peichao Lu, Wosenu Mergo, Daniel Mutnick, Folkert Reck, Alexey Rivkin, Colin Keith Skepper, Xiaojing Michael Wang, Jianhua Xia, Yongjin Xu
  • Patent number: 10160695
    Abstract: Disclosed herein are methods for the fluorination aromatic N-heterocyclic N-oxides that comprise at least one leaving group. The N-oxides may be reduced to the fluorinated aromatic N-heterocyclic amine analogs. This novel fluorination approach may be successfully applied for synthesizing aromatic N-heterocyclic compounds labeled with 18F.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: December 25, 2018
    Assignee: The University of Chicago
    Inventor: Pedro Brugarolas
  • Patent number: 10160725
    Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 25, 2018
    Assignee: MICROBIAL CHEMISTRY RESEARCH FOUNDATION
    Inventors: Manabu Kawada, Hikaru Abe, Takumi Watanabe, Hiroyuki Inoue, Shun-ichi Ohba, Chigusa Hayashi, Masayuki Igarashi
  • Patent number: 10155744
    Abstract: A medicament or pharmaceutical composition for the treatment of a respiratory tract disease, which is a compound having the following formula: or a pharmaceutically acceptable salt thereof. A method of treating a respiratory tract disease includes administering to a patient an effective amount of the compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 18, 2018
    Assignee: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
    Inventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova
  • Patent number: 10158091
    Abstract: The complexes disclosed herein are cyclometalated metal complexes of Formula (I) that are useful for full color displays and lighting applications.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: December 18, 2018
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Zhi-Qiang Zhu
  • Patent number: 10155745
    Abstract: A medicament or pharmaceutical composition for the treatment of exacerbations of asthma and chronic obstructive pulmonary disease, which is a compound having the following formula: or a pharmaceutically acceptable salt thereof. A method of treating exacerbations of asthma and chronic obstructive pulmonary disease includes administering to a patient an effective amount of the compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 18, 2018
    Assignee: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
    Inventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova
  • Patent number: 10154993
    Abstract: [Problem] To provide a novel pharmaceutical composition which can suppress delayed, release of the compound represented in general formula (1) or a salt thereof. [Solution] This solid pharmaceutical composition contains the compound represented in general formula (1), or a salt thereof, and a salting-out agent.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: December 18, 2018
    Assignee: KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Uchida, Masataka Hanada, Yoshikazu Miyazaki
  • Patent number: 10155739
    Abstract: Halogenated S-(perfluoroalkyl)dibenzothiophenium salt represented by the following general formula (I): This compound is a new, reactive, and industrially useful reagent for perfluoroalkylating organic compounds. The reagent can be prepared by a one-pot process or a two-step reaction process from a halogenated biphenyl and easily isolated by a filtration method. In addition, the halogenated biphenyl can be recovered by desulfurization from a halogenated dibenzothiophene obtained as a side-product by the usage of the reagent.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: December 18, 2018
    Inventors: Teruo Umemoto, Bin Zhang, Tianhao Zhu, Xiaocong Zhou, Yuanqiang Li
  • Patent number: 10155743
    Abstract: Biologically active glutarimide derivatives of the following formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 18, 2018
    Assignee: Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmaenterprises”
    Inventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova